Evidence map›Paper›PMID 42284542›Full record

Observational studyJCO precision oncology2026

Constitutional

Mohamad Kayali, Eric Hahnen, Alexander Burges, Alexander Reuss, Julia Caro-Valenzuela, Nikolaus de Gregorio, Florian Heitz, Sandra Schmidt, Frederik Marmé, Felix Hilpert and 11 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mohamad KayaliCenter for Familial Breast and Ovarian Cancer, Institute for Hereditary Cancers, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Eric HahnenCenter for Familial Breast and Ovarian Cancer, Institute for Hereditary Cancers, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-1152-8367
Alexander BurgesDepartment of Gynecology, University Hospital Munich-Großhadern, Munich, Germany.ORCID 0000-0002-9693-366X
Alexander ReussCoordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany.ORCID 0009-0002-8804-4122
Julia Caro-ValenzuelaCenter for Familial Breast and Ovarian Cancer, Institute for Hereditary Cancers, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-1751-1638
Nikolaus de GregorioDepartment of Gynecology, Klinikum am Gesundbrunnen, SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany.
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany.ORCID 0000-0002-2412-0352
Sandra SchmidtCenter for Familial Breast and Ovarian Cancer, Institute for Hereditary Cancers, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Frederik MarméDepartment of Gynecology, University Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany.ORCID 0000-0002-6591-3367
Felix HilpertDepartment of Gynecology, University of Kiel, Kiel, Germany.ORCID 0000-0002-3492-9577
Pauline WimbergerDepartment of Carl-Gustav-Carus University, Technische Universität Dresden and National Cancer Center (NCT Dresden), Dresden, Germany.ORCID 0000-0002-7380-577X
Stefan KommossDepartment of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Katharina PrieskeOnkologisches Therapiezentrum, Krankenhaus Jerusalem, Hamburg, Germany.
Christoph EngelInstitute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.ORCID 0000-0002-7247-282X
Paul BuderathDepartment of Gynecology, University of Essen, Essen, Germany.
Dimo DietrichDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Bonn, Bonn, Germany.ORCID 0000-0001-9794-7927
Rita SchmutzlerCenter for Familial Breast and Ovarian Cancer, Institute for Hereditary Cancers, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jalid SehouliDepartment of Gynecology and Gynecological Oncology, Charité, Campus Virchow, Berlin, Germany.ORCID 0000-0002-5963-6623
Kerstin RhiemCenter for Familial Breast and Ovarian Cancer, Institute for Hereditary Cancers, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Philipp HarterDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany.ORCID 0000-0002-9663-5005
Jan HaukeCenter for Familial Breast and Ovarian Cancer, Institute for Hereditary Cancers, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0001-8236-4075

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeConstitutional epimutations arise early in development and are present across normal tissues, including peripheral blood. Constitutional MATERIALS AND

methods

results

conclusionConstitutional

Indexed as

BRCA1 ProteinDNA MethylationOvarian NeoplasmsPromoter Regions, GeneticAdultAgedFemaleHumansMiddle AgedRetrospective StudiesBRCA1 ProteinBRCA1 protein, human

Identifiers

PMID42284542
PMCPMC13268109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.